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Our 2020 Vision for Health and Social Care sets out our ambitions that by the year 
2020 everyone in Scotland is able to live longer healthier lives at home, or in a 
homely setting. 
 
It strives for a healthcare system where we have integrated health and social care,   
a focus on prevention, anticipation and supported self-management. When hospital 
treatment is required, and cannot be provided in a community setting, day case 
treatment will be the norm.  
 
Whatever the setting, care will be provided to the highest standards of quality and 
safety, with the person at the centre of all decisions. There will be a focus on 
ensuring that people get back into their home or community environment as soon as 
appropriate, with minimal risk of re-admission. 
 
The Vision and Action Plan set out in this document reaffirms the contribution of the 
pharmacist and the pharmaceutical care they provide in our future healthcare 
system. It builds on the direction of travel of our progressive and developing policy 
landscape for high quality, sustainable health and social care, and the 
comprehensive study on NHS pharmaceutical care undertaken by Dr Hamish Wilson 
and Professor Nick Barber last year. 
 
Importantly, the Vision and Action Plan recognises that the integrated delivery of 
care, as set out in the 2020 Vision Route Map, will require the delivery of NHS 
pharmaceutical care to adapt new and innovative models to facilitate professional 
independence of pharmacists, working in collaborative partnerships with other health 
and social care professionals and the third sector to deliver the best possible health 
outcomes for patients from their medicines.  
 
Consistent with the ambitions of the Quality Strategy and 2020 Vision, our overriding 
objective is that all patients, regardless of their age and setting of care, will receive 
high quality pharmaceutical care using the clinical skills of the pharmacist to their full 
potential. This Vision and Action Plan recognises the continuing and important role of 
pharmacists located in our communities and high streets across Scotland, and 
considers their future relationship with other local healthcare provision. This will be 
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crucial for future service planning in remote and rural areas and in our most deprived 
communities. 
 
Over the years, NHS pharmaceutical care in Scotland has attracted a well-earned 
UK and international reputation for innovative models of care.  Our Vision and Action 
Plan aims to keep Scotland at the forefront of innovation and high quality 
pharmaceutical care, and its contribution towards our shared goal of world-leading 
healthcare. 
 
I am grateful to all those who contributed to the review conducted by Dr Wilson and 
Professor Barber, and look forward to your continued support and engagement as 






















This Vision and Action Plan, Prescription for Excellence, complements the Scottish 
Government’s 2020 Vision Route Map and Quality Strategy Ambitions.  It plays to 
the strengths of pharmacists as experts in the therapeutic use of medicines and their 
potential contribution and integration into health and social care teams. 
 
Over the next decade and beyond, advances in health care will continue to 
accelerate.  In particular significant changes will occur in medicine and therapeutics 
which will require new and innovative models of care to enable patients to obtain the 
maximum benefit.  The patient is a critical member of the health and social care 
team and requires to be given enough information to enable them to make informed 
decisions about their care.  This is key to delivering person-centred healthcare. 
 
Pharmaceutical care is a key component of safe and effective healthcare.  It involves 
a model of pharmacy practice which requires pharmacists to work in partnership with 
patients and other health and social care professionals to obtain optimal outcomes 
with medicines and eliminate adverse events whenever possible. Patients regardless 
of their setting should receive high quality pharmaceutical care.  This is particularly 
important for patients with complex health issues including multimorbidities and 
those in care homes.  
 
Dispensing doctors play an essential role in the dispensing and supply of medicines 
to patients in rural communities.  Going forward pharmaceutical care provision 
should complement and support dispensing doctors’ services and their patients.  
 
These aspirations have resulted in our Vision that all pharmacists providing NHS 
pharmaceutical care will be NHS accredited clinical pharmacist independent 
prescribers working in collaborative partnerships with medical practitioners who will 
continue to have overall responsibility for diagnosis.  An essential role of the clinical 
pharmacist working within the team will be to initially assess the patient for potential 
issues to help inform the choice of medication. In addition they will be responsible for 
the continual monitoring of the effects and side effects of the medicines and making 
adjustments to dose and therapeutic agent within agreed parameters. 
 
The NHS continues to face increasing workplace pressures.  The inclusion of the 
NHS accredited clinical pharmacists into the primary care team is intended to 
increase the clinical capacity and assist in addressing the increasing demands in 
primary care as our population ages and the complexity of their care increases. 
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Critical to collaborative working is education and training in a multi-disciplinary 
context at both undergraduate and postgraduate level.  Work is already underway in 
this area between NHS Education Scotland (NES) and the Scottish Schools of 
Medicine and Schools of Pharmacy at undergraduate level.  This will set the agenda 
for future collegiate and collaborative working between the medical and pharmacy 
professions in Scotland. 
 
Finally I want to turn to professionalism.  Professionalism can be defined by a set of 
values, behaviours and relationships. It encompasses aspects such as commitment, 
integrity, honesty, a sense of service, accountability, independent judgement and 
individual responsibility and is underpinned by a culture of continuous improvement. 
It is therefore fundamentally important that pharmacists, regardless of employer or 
environment, are able to make professional decisions for their patients at all times.  
New and innovative models to facilitate the professional independence of 
pharmacists will be explored as a priority in this Action Plan. 
 
In order to deliver this Vision and Action Plan, I will establish a governance structure 
within the Scottish Government Health and Social Care Directorates to provide a 
detailed work plan and establish implementation groups with representatives from all 
the key stakeholders.  This will involve cooperative working with the NHS, the 
pharmacy and medical professions, patients, the public and the regulatory bodies. 
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  Executive Summary  
 
Our Vision:  Prescription for Excellence 
 
All patients, regardless of their age and setting of care, receive high quality 
pharmaceutical care from clinical pharmacist independent prescribers. This 
will be delivered through collaborative partnerships with the patient, carer, GP 
and the other relevant health, social care, third and independent sector 
professionals so that every patient gets the best possible outcomes from their 




The Scottish Government Vision for healthcare is that by 2020 
everyone is able to live longer healthier lives at home, or in a 
homely setting. 
 
Integrated delivery of care as set out in the 2020 route map will 
require new and innovative approaches to pharmaceutical 
care1 in Scotland.  Our Vision described in the driver diagram 
(Figure 1) begins to set out how the future of NHS 
Pharmaceutical Care in Scotland will contribute to the 2020 
Vision and Route Map.  The Vision will significantly contribute 
to 10 of the 12 priority areas identified in the route map. 
 
The aim is to create models of care that are safe, effective and 
person centred, provide long term sustainability and facilitate 
and design an environment for pharmacists to engage with 
other health and social care professionals. 
 
In order to release capacity to deliver the clinical role, the 
dispensing process may benefit from better use of pharmacy 
technicians and be largely automated and managed by them.  
In addition, using technology to deliver clinical care more 
effectively will need to be embedded into practice. 
 
NHS Pharmaceutical Care in the community would not be 
reliant solely on delivery from a high street pharmacy.  Delivery 
through a distributed model from GP practices, the domiciliary 
setting or via remote consultations using telehealth are among 
the models that should be explored. Pharmaceutical care 
provision by pharmacists should also complement and support 
patients served by dispensing doctors. This distributed model 




 Helper DD et al, Am J Pharm Educ 1989. 2.Hepler CD, Strand LM. March 1990. Opportunities and 
responsibilities in pharmaceutical care. American Journal of Hospital Pharmacy, Volume 47, pages 
533-543 
This Vision will 
significantly 
contribute to the 
following 10 of the 
12 priority areas of 
the 2020 Route 
map below: 
 person centred 
care 
 safe care 




 integrated care 







 efficiency and 
productivity 
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should ensure that all patients have equitable access to NHS 
pharmaceutical care. 
 
By 2023 all pharmacists will require to be NHS accredited clinical 
pharmacist2 independent prescribers in order to provide clinical 
care to patients in the community. They will be referred to as 
general practice clinical pharmacists regardless of the setting in 
which they work. In the management of long term conditions they 
will work in partnership with the medical profession so that post 
diagnosis caseloads can be allocated to these pharmacists to 
optimise their complementary skills.  
 
Clinical use of medicines continues to become increasingly 
complex.  One reason for this results from new developments in 
translational genomics, for example, stratified medicine.  
Stratified medicine is a developing concept where using genetic 
analysis of patients’ likelihood of benefiting from particular drugs 
will allow for more specific targeting of drug treatment. 
 
Changes to the delivery of healthcare described in the Quality 
Strategy, and the advancement of therapeutics (use of 
medicines), places greater emphasis on the need for healthcare 
teams in hospital and community to work closely together. In 
addition, some medicines, which previously were only able to be 
administered in the hospital setting, are now provided to patients 
in their own home due to advances in technology and medicine 
design.  It follows, therefore, that NHS pharmaceutical services 
should undergo significant redesign in order to enable 
pharmacists to play their part in delivering safe and effective care. 
 
Advances in technology, robotic dispensing and telehealth would 
need to be harnessed to contribute to a health service fit for the 
21st century.  This will be part of the work programme to deliver 
the Scottish Government’s Vision for innovative NHS 
pharmaceutical care. 
 
The Route Map to the 2020 Vision for Health and Social Care3 
describes the way in which the NHS and Local Authorities will 
work together and in partnership with the third and independent 
sectors, to ensure a more seamless experience for the service 
user and carer.  This adds a further dimension to the importance 
of pharmaceutical care in the community and the therapeutic 
partnerships needed to underpin that4.  It acknowledges the 
issues facing Scotland such as inequalities, an ageing population, 
increasing multimorbidities (e.g. two or more long term 
                                               
2 Clinical Pharmacy Defined, Pharmacotherapy 2008;28(6):816-817. 
3 A Route Map to the 2020 Vision for Health and Social care, Scottish Government, 2013. 
4
 Establishing Effective Therapeutic Partnerships - A generic framework to underpin the Chronic 
Medication Service element of the Community Pharmacy Contract, Scottish Government, December 
2009.   
 
Pharmaceutical 
care is the 
responsible 






quality of life. It 
involves 
cooperation with 
the patient, and 
if appropriate 








care plan that 
will produce a 
specific 
therapeutic 
outcome for the 
patient. 
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conditions), and increasing expectation from new drugs, treatments and 
technologies. 
 
The focus is on improving outcomes for people by providing consistency in the 
quality of services, ensuring people are not unnecessarily delayed in hospital, and 
maintaining independence by creating services that allow people to stay safely at 
home for longer.  It encapsulates a transformation in public service working and 
establishes a milestone in the wider agenda of the Scottish Government's 
programme of reform. 
 
At the end of each chapter we have set out the main areas considered to 
deliver the vision.  This work will be taken forward under a governance 
structure in the Scottish Government Health Directorates to consider each of 
the areas identified for development and to provide a detailed work 
programme and delivery plans. 
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  Chapter 1   The Vision  
 
1.1 The Vision 
 
1.1.1 Our Vision as set out in the driver diagram (Figure 1) identifies four key 
 patient populations, each with specific pharmaceutical care needs: people in 
 the community; patients receiving care at home; residents in care homes; and 
 patients receiving care in hospital / specialist hospital care at home.  It 
 focuses not on the physical registered pharmacy premises, but rather on the 
 clinical capability of pharmacists working in a variety of environments to meet 
 those care needs in partnership with other medical and social care 
 professionals. 
 
1.1.2 Our success in delivering the Vision will be measured through the 
 delivery of the following main outcomes through a series of work 
 programmes which will be delivered over the next 10 years. 
 
 
 Pharmacists in the NHS would be recognised as clinicians responsible for 
the provision of NHS pharmaceutical care.  
 
 Releasing capacity of pharmacists to deliver pharmaceutical care would be 
facilitated by full utilisation of pharmacy technicians, support staff and 
increased use of robotics in dispensing to improve safety and efficiency. 
 
 All patients would have access to NHS pharmaceutical care by NHS 
accredited clinical pharmacist independent prescribers in all settings. 
 
 Pharmacists in secondary care and in primary care work together in an 
integrated way which would be supported by a common clinical pharmacy 
career structure. 
 
 Patients have a close relationship with an individual pharmacist, ensuring 
greater continuity and consistency of care for patients - introducing the 
concept of the named pharmacist and patient registration with NHS Board 
listed pharmacists which will underpin professional relationship with 
patients and local clinical governance systems. 
 
 NHS Boards to have a direct relationship with individual pharmacists 
providing services in their areas regardless of setting. 
 
 Pharmacists work closely with GPs, primary care, community teams and 
secondary care sharing information for the benefit of the patient. These 
pharmacists would be known as the general practice pharmacists. 
 
 Pharmacists work in groups to deliver NHS Pharmaceutical care to patients 
in all care settings, especially for those with complex or long term 
conditions with allocation of caseloads. 
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 Pharmaceutical care for specific patient groups is provided under a 
national frame work and to nationally determined NHS standards. A 
national framework and NHS standards for the pharmaceutical care of 
residents of care homes and people receiving care and support at home 
would be prioritised. 
 
 NHS Board Pharmaceutical Care Services Plans with needs assessments to 
enhance local healthcare planning which would include equitable access to 
services in deprived areas as well as specific public health needs driving a 
new contractual framework for premises and pharmaceutical care, 
removing any perverse incentives. 
 
 The Scottish Government will work with patients, dispensing doctors and 
appropriate stakeholders to explore how rural communities can be further 
supported in terms of pharmaceutical care. 
 
 Pharmacists undertake an enhanced role in preventing ill-health,              
co-production and minimising health inequalities. 
 
 Pharmacists and the wider pharmacy workforce are trained appropriately to 
their enhanced role, both pre and post qualification. 
 
 NHS boards would provide professional and clinical leadership for all 
pharmacists providing NHS pharmaceutical care services. 
 
 
Drivers for Change and Evidence 
 
1.1.3 Some of the additional drivers for change are listed in Appendix 1.  Alongside 
 the Wilson and Barber Review5, a number of other key documents, reports 
 and pilots have provided evidence for the development of the Vision.  They 
 are listed in Appendix 2.  Appendix 3 acknowledges the achievements 
 through The Right Medicine6.  
                                               
5
 Review of NHS Pharmaceutical Care of Patients in the Community in Scotland –Dr H Wilson and 
Professor N Barber, Scottish Government, August 2013. 
6
 The Right Medicine: A Strategy for Pharmaceutical Care in Scotland, Scottish Government, 2002. 
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Patient Journey in 2020 
 
 
For me the way I look after my health has changed over the last 5 years.  Last year I went into 
hospital after a heart attack.  I had suffered for 3 years previously with angina and also more 
recently had problems with my breathing which had started a couple of winters ago after a chest 
infection.  My GP told me I had chronic obstructive airways disease (COPD) which had been 
caused by my years of smoking and that it could get worse if I didn’t stop smoking.  I had been a 
smoker for over 40 years and at the age of 63 I felt too old to be breaking old habits!  My GP had 
asked me to see the pharmacist who worked closely with my GP for a review of my breathing 
after a chest infection. Before this I had only seen my pharmacist for advice for winter ailments as 
I was on a list of medications.  The pharmacist gave me a self-management plan for my 
breathing and showed me how to monitor my treatment, I felt much more in control and knew I 
could ask for help when needed.  After this one weekend I felt my chest was flaring up and after 
getting advice from the pharmacist started to take my antibiotics that she had prescribed as a 
standby.  It was wonderful as normally I am ill for weeks afterwards as I normally wait until I am 
really poorly before I make an appointment to see my GP. After this the pharmacist provided me 
with support and prescribed treatment to help me stop smoking.  It took me a while but she was 
very supportive and helped talk though all the issues that I had.  Its six months since I quit and I 
am less breathless.  My breathlessness score is better and I have not had so many chest 
infections. 
 
Anyway, when I was admitted to hospital, the pharmacist gave the pharmacist in hospital a list of 
my tablets that I was taking.  Just as well as in the shock of it all, I had forgotten the new one I 
had been started on.  After my heart attack, I was put onto some additional medicines and the 
dose of others was increased.  The pharmacist in the hospital had sent all my medication 
changes to my pharmacist who reviewed all my medication and then ran through the changes 
with me.  I couldn’t understand why I was taking a higher strength of my cholesterol tablets and 
also why I needed a new tablet for my heart as my blood pressure was fine.  The pharmacist 
working with my GP sees me every six months to manage my COPD and heart conditions and I 
see the GP when I need to.  
 
They record everything on one system so the GP and pharmacist both seem to know what’s 
going on with my care. It seems like a great team effort.  
Deliver NHS 
pharmaceutical 








social care and 
hospital settings 





and other health 
and social care 
professionals 






the right time and  
to ensure that all 





between patients, their families 
and those delivering health and 
social care services ensure person 
centred appropriate treatment and 
interventions are delivered
Delivery of treatments, 
interventions, support and 
services will be delivered in a safe 
environment preventing injury or 
harm to people from medicines, 
advice and support 
• Clinical pharmacist independent prescribers to deliver 
medication/polypharmacy review
• Prescribing of medicines after diagnosis/genetic testing: 
stratified medicines, pharmacovigilance by pharmacists
• Allocate case load to pharmacists for management of LTC  
by patient registration with named pharmacist
• Focus on prevention and anticipatory care planning 
• Enhance patient access to common clinical conditions 
• Work in partnership with patients and carers to improve 
adherence and facilitate co-production
• Through Local area drug and therapeutics implement in 
practice appropriate use of medicines & evidence based 
guidance
• Use of patient identifiable prescribing data to monitor 
prescribing
• Implements Scottish Patient Safety & medicines 
reconciliation Programme across pharmacies in primary care 
& secondary care
• Use of SPARRA data for targeted at risk patients
• Ensure standards of medicines supplied
• Domiciliary visits /telehealth /apps
• Service models for high risk and high 
tech medicines and poly pharmacy
• Long term  Medication Service
• Pharmaceutical care for specific 
patient groups and services 
• Enhance role of pharmacists through 
Therapeutic Partnerships Patient 
registration
• Scottish Patient Safety Programme 
delivered via pharmacists working in 
the community
• Evidence based guidance using 
patient data
• Patient level risk assessments
• Clinical governance & cost effective 
use of existing, new medicines and 
technologies
• Performers list
 Vision                                                  Primary Drivers (what)                                                        Secondary Drivers (how)                     Ideas for Change
Figure 1: VISION FOR FUTURE NHS PHARMACEUTICAL CARE OF PATIENTS IN SCOTLAND
Prescription for Excellence: A Vision and Action Plan
Outcome measures
All patients by 2023 have 
access to appropriate 
pharmaceutical care 
delivered by clinical 
pharmacist independent 
prescribers on NHS 
performers list
People in the community        
Delivered by Pharmacist collaboratively working across Social Work Interface/GP Practice and Nursing interface/Primary Secondary care interface
Patients receiving care at home Residents in care homes        Patients receiving care in hospital/specialist hospital care at home
Effective appropriate treatment, 
interventions, support and 
services will be provided at the 
right time, reducing waste, harm 
and variation and ensuring clinical 
and cost effective use of existing, 
new medicines and technologies
Development of infrastructure 
supports pharmacy practice 
development, education, 
research and electronic sharing 
of information
• Use of pharmacy team and automate supply of medicines 
using robotics to release time for clinical care 
• Integration of primary and secondary care pharmacists to 
improve interface issues
• Routine dispensing transferred to serial dispensing
• Provision for Homecare coordinated through pharmacies 
including pharmaceutical care provision for hospital at home
• Education and training to support multi disciplinary learning 
and working
• Implementation of professional skills to ensure standards 
of practice for NHS services are attained through NES, 
professional bodies and Schools of Pharmacy
• Ensure electronic access to  appropriate clinical information 
that contributes to pharmaceutical care
• Primary and secondary configured systems to allow 
electronic sharing and  prescribing for all pharmacists
• Use of telehealthcare including mobile apps to monitor 
patients with long term conditions
• Research and development to improve pharmaceutical care
• Reduce harmful and wasteful 
variation in prescribing
• Needs assessment
• Role of group practice and general 
practice clinical pharmacist
• Utilising skills of pharmacy team
• Establish robotics in pharmacies 
• Modern framework for services
• Workforce/education/career 
framework 
• Clinical and professional leadership
• All pharmacists delivering clinical 
services will be independent 
prescribers
• Integrated IT systems
• Use of telehealthcare
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1.2 The Future 
 
1.2.1 This Action Plan provides a vehicle to deliver pharmaceutical care of NHS 
 patients fit for the 21st century.  Pharmacists are highly qualified and skilled 
 healthcare professionals who make a significant contribution to healthcare in 
 Scotland, however their full potential is yet to be fully utilised within NHS 
 Scotland to help deliver the 2020 Vision for health and social care. 
 
1.2.2 The Government’s manifesto contains a commitment “to further enhance the 
 role of pharmacists, building on the introduction of the Chronic Medication 
 Service, and encourage even closer joint working between GPs, pharmacists 
 and other community services …” 
 
1.2.3 This Action Plan recognises the important traditional role of the supply of 
 medicines from registered pharmacies located in high streets across 
 Scotland.  Scottish Government Health and Social Care Directorates will 
 continue to work with pharmacy owners and NHS Boards to ensure an 
efficient and cost effective pharmacy network for the 
supply and dispensing of NHS prescriptions and other 
aspects of NHS pharmaceutical services which are 
best delivered from registered pharmacy premises. 
 
However, integrated delivery of care, as set out in the 
2020 route map, will require the delivery of NHS 
pharmaceutical care to consider new and innovative 
models to facilitate professional independence of 
pharmacists working in partnership with other health 
and social care professionals and the third sector.  
These new and innovative models will explore, for 
example, the concept of clinical pharmacist group 
practices to complement the traditional pharmacy 
network. 
 
1.2.4 In the future, pharmacists delivering NHS pharmaceutical care should be 
 clinical pharmacist independent prescribers, who may have allocated 
 workloads to target their clinical skills to patients who would most benefit from 
 the continuity of care provided, by working in partnership with the medical 
 profession to optimise the use of medication which would include monitoring 
 and adjusting treatment. 
 
1.2.5 The Vision also builds on the pharmacist’s role in encouraging and supporting 
 the individual patient to manage their own condition(s) which is central to the 
 concept of Co-production.  Co-production is the process of active dialogue 
 and engagement between people who use services and those that provide 
 them, putting the service user on the same level as service provider.              
 Co-production recognises that each of us has skills and knowledge, and the 
 ability to develop these.  It also recognises that access to support from family, 
 neighbourhood and community allows for greater independence.   
A Clinical pharmacist 
provides patient care that 
optimises care and use of 
medicines for patients in all 
settings often collaborating 
with medical and other 
healthcare professionals. 
Clinical pharmacists are 
regarded as the experts in 
therapeutic use of medicines 






 Co-production designs support and services around what people can do for 
 themselves, rather than seeking to make them more dependent.  It offers the 
 potential to enhance both quality of life and longevity through focusing on the 
 assets that promote the self-esteem and coping abilities of individuals and 
 communities.  
 
1.2.6 Pharmacists have a role in the healthcare team to monitor the adverse effects 
 of medicines as well as their clinical performance to optimise their safe and 
 effective use.  This is known as pharmacovigilence.  Monitoring patient 
 outcomes when treated with new medicines presents opportunities for closer 
 working between the medical and pharmaceutical professions and the 
 pharmaceutical industry. 
 
1.2.7 The Wilson and Barber Review7 highlighted that patients would generally 
 welcome greater continuity around the pharmacist providing their 
 pharmaceutical care.  In addition, evaluation of the smoking cessation 
 component of the community pharmacy Public Health Service8 found that 
 outcomes were often better for patients when they regularly saw the same 
 member of pharmacy staff. 
 
 Scottish Government believes that more needs to be done to provide 
 consistency and continuity and the concept of the named pharmacist will be 
 explored when considering the delivery of NHS pharmaceutical care. 
 
1.2.8 NHS Boards are responsible and accountable for the provision of 
 pharmaceutical services in secondary and primary care sectors.  Currently in 
 primary care, NHS Boards make arrangements with pharmacy owners for the 
 delivery of pharmaceutical services.  The pharmacist delivering these services 
 needs to ensure that their priorities are focused on the patient above all else.  
 Perverse incentives such as targets and bonuses based on commercial retail 
 priorities should not be allowed to adversely affect patient care.  
 
 Scottish Government will explore new and innovative models to facilitate the 
 professional independence of the pharmacists delivering care to patients. 
 
1.2.9 For an ageing population that has increasing multiple morbidities (more than 
 one medical condition), delivery of NHS pharmaceutical care to all patients in 
 all settings is essential.  However, it requires a step change in establishing 
 collaborative partnerships within an integrated health and social care system 




                                               
7
 Review of NHS Pharmaceutical Care of Patients in the Community in Scotland, Scottish 
Government, August 2013. 
8
 Review of the Community Pharmacy Public Health Service for Smoking Cessation and Emergency 
Hormonal Contraception, Scottish Government, November 2011. 





1.2.10 Medication is by far the most common form of healthcare intervention.  Four 
 out of five people aged over 75 years take a prescription medicine and 36 per 
 cent are taking four or more9.  However, it is suggested that up to 50 per cent 
 of drugs are not taken as prescribed, many drugs in common use can cause 
 problems and that adverse reactions to medicines are implicated in 5 - 17 per 
 cent of hospital admissions10.  
 
1.2.11 Research has demonstrated that patients on multiple medications are more 
 likely to suffer drug side effects and that this is more related to the number of 
 multiple morbidities a patient has than age.  There is a clear and steady
 increase in the number of people admitted to hospital with drug adverse 
 effects11.  Individuals admitted with one drug side effect are more than twice 
 as likely to be admitted with another.  This situation can be accentuated by 
 altered pharmacodynamics and pharmacokinetics (changes in how the body 
 deals with drugs) associated with either ageing or illness. 
 
1.2.12 A top priority in pharmaceutical care is to prevent predictable side effects and 
 optimise clinical outcomes with medication. 
 
1.2.13 The Wilson and Barber Review highlighted particular concerns about the 
 pharmaceutical care of both residents in care homes and those where care at 
 home services are provided within social care arrangements. 
 
 This Action Plan prioritises these areas for early consideration with regard to 
 new and innovative ways of service delivery.  This will also include 
 consideration of any issues which may adversely affect the care of patients in 
 these environments. 
 
1.2.14 The hospital sector is responsible for the provision of treatment of those 
 patients living in their homes but still receiving specialist care by their hospital 
 consultant.  This is an expanding area of healthcare and presents opportunity 
 to explore innovative pharmaceutical care provided through integrated 
 working between the hospital, community pharmacists, medical practitioners 
 and the pharmaceutical industry. 
 
1.2.15 In some parts of rural Scotland, the NHS relies on dispensing doctors to 
 provide dispensing services to their own patients who (through geography and 
 demographics) are unable to secure the dispensing services of a community 
 pharmacy.  In these cases the dispensing doctor service plays a vital role in 
 the provision of NHS medicines. 
 
 The Scottish Government will work with patients, dispensing doctors and 
 appropriate stakeholders to explore how rural communities can be further 
 supported in terms of pharmaceutical care. 
                                               
9
 Quality and Outwork framework, NHS Employers, 2012. 
10
 Co-morbidity and repeat admission to hospital for adverse drug reactions in older adults: 
retrospective cohort study, M Zhang et al, BMJ 2009;338:a275. 
11
 Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients 
M Pirmohamed et al, BMJ  2004;329:15-19. 





1.2.16 Central to the future development of NHS pharmaceutical care is the 
 importance of sharing of patient information between pharmacist delivering 
 NHS services and other health and social care professionals in secure and 
 confidential systems.  This will be explored with patients, the medical and 
 pharmaceutical professions, the NHS and other relevant key stakeholders. 
 
1.2.17 The delivery of future innovative pharmaceutical care may require novel 
 models for clinical practice and joint working which will create new demands 
 on undergraduate and postgraduate education.  These opportunities will be 
 explored with NES, the professional bodies and the Schools of Pharmacy and 
 Medical Schools in Scottish Universities. 
 
1.2.18 The development of innovative pharmaceutical care will take place over the 
 next 10 years and will focus on the three key Quality Ambitions, namely: 
 person-centred, safe and effective care.   
 
 The Vision and Action Plan will be delivered through joint working between 
 Scottish Government, NHS Scotland, health and social care professionals, 





 Our Action Plan will build on the recommendations of the Wilson and Barber 
 Review and related health and social care policy, and will clearly position the 
 pharmacist’s contribution to delivering measureable  progress in support of the 
 2020 Vision and Route Map. 
 
 This work will be taken forward under a governance structure with the Scottish 
 Government Health and Social Care Directorates to consider each of the 
 areas identified for development, and to provide a detailed work programme 
 and delivery plans.  It will also take into account any additional requirements 
 resulting from the implementation of the 2020 Vision. 
 
 Chapters 2-5 set out the Action Plan as the three main aims of the quality 
 ambitions, person centred, safe and effective with the  underpinning of the 
 infrastructure that will be needed for delivery.  At the end of each chapter we 
 have set out the main areas to deliver the Vision.  
 





   Chapter 2        Person-centred Pharmaceutical Care and Medicines 
 
In this Chapter we will set out our aims and proposed work 
programme to deliver person-centred pharmaceutical care.   
This will focus on developing approaches to: 
 
 Embed partnership working between the patient (and/or 
 carer), their GP and pharmacist  -  therapeutic 
 partnerships - and with other health and social care 
 professionals. 
 
 Further enhance the role of Pharmacist independent  
 prescribers who will work with GP’s to deliver 
 medication/polypharmacy review, using telehealthcare 
 and domiciliary visits where appropriate. 
 
 Further develop the pharmacist’s contribution to the 
 management of common clinical conditions and develop 
 new models of delivery of primary care services in 
 partnership with GP’s. 
 
 Explore making better use of pharmacist prescribing 
 post diagnosis. 
 
 Introduce innovative pharmaceutical care to support the 
 clinical application of translational genomics and  
 stratified medicines. 
 
 Enhance the role of pharmacists in pharmacovigilance 
 (monitoring) within NHS secondary and primary care. 
 
 Introduce and establish case loads to pharmacists to 
 contribute to the clinical management of Long Term 
 Conditions by developing the concept for registration 
 with a ‘named pharmacist’ for all pharmaceutical care 
 needs throughout the patient journey. 
 
 Embed prevention, anticipatory care planning and early intervention into 
pharmaceutical care. 
 
 Utilise the application of systems for the risk assessment of patients to 
prioritise care – e.g. tools such as Scottish Patients At Risk of Readmission 
(SPARRA). 
 
 Develop new NHS standard specifications for services and innovative 
pharmaceutical care for specific patient groups developed with the 
professions. 
 
 Improve and enhance pharmacists’ role in working in partnership with 
patients and carers to improve co-production and support                        

























2.1 Introduction  
2.1.1 Person-centred pharmaceutical care and medicines is pivotal in delivering our 
 Vision over the next 10 years.  In this Chapter, we will focus on our aims and 
 objectives to deliver mutually beneficial partnerships between patients, their 
 families, carers and those delivering health and social care services.  
 Importantly, it will set out our approach to help ensure patients have 
 appropriate treatment and interventions with medicines which respect 
 individual needs and values demonstrating compassion, continuity of care, 
 clear communication and shared decision-making. 
 
2.2 Scotland’s Population and Medicines Use 
2.2.1 The changing demography of Scotland, the associated increase in people 
 living with complex and long term conditions (multimorbidity) and the 
 continuing health inequalities set major challenges for the provision of 
 pharmaceutical care in the future.  The proportion of over 75s, who are high 
 users of health and care services and for whom prescribing can be particularly 
 complex, will increase by over 25% in the next 10 years, and the number of 
 over 75s is likely to have increased by almost 60% in the next 20 years12. The 
 pattern of disease will see a continuing shift towards long term conditions, 
 with growing numbers who will have multimorbidities. In particular the 
 combination of physical and mental health disorders can produce additionally 
 complex needs.  
 
2.2.2 In a recent Scottish study13 an analysis of a database of over one and three 
 quarter million patients found that nearly a quarter had multimorbidity, that  the 
 onset of multimorbidity occurred 10-15 years earlier in people living in the 
 most deprived areas compared with the most affluent.  Also, that the presence 
 of a mental health disorder increased as the number of physical morbidities 
 increased. 
 
2.2.3 The study illustrates the challenges to the traditional single-disease 
 framework to which most health care has been configured and underlines the 
 importance of generalist clinicians providing personalised, comprehensive and 
 continuous care. 
 
2.3 Non-adherence to prescribed medicine regimens   
2.3.1 Non-adherence (where medications are not taken as prescribed) has been 
 estimated to be responsible for 48% of asthma deaths, an 80% increased risk 
 of death in diabetes and a 3.8-fold increased risk of death following a heart 
 attack14.  Another manifestation of non-adherence is failure to collect 
 prescriptions.  Two small studies show that 2.9 - 5.2% of items prescribed 
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 were not dispensed15, although they were conducted before the introduction 
 of free prescriptions.  It is estimated that one pound in every eight of NHS 
 spending is on medicines, however up to half of all the medicines prescribed 
 are not used as the prescriber intended16.  
 
2.3.2 Waste medicines result predominantly from non-adherence, changes in 
 prescribing and changes in the patient’s condition.  A study17 of waste 
 medicines in England in 2010 found that medicines worth around £300 million 
 were wasted per year and about £150 million could be saved in cost effective 
 ways.  The proportionate equivalent for Scotland would be wastage of         
 £30 million and potential savings of £15 million.  The study concludes that ‘the 
 greatest social and economic returns are to be gained when reducing 
 medicines waste can be effectively linked to improving care quality and health 
 outcomes’ including patient safety. 
 
2.3.3 Pharmacists are ideally placed to work with patients to support co production 
 in managing their medications.  The European Innovation Partnership in 
 Active and Healthy Aging has an Action Group focused on improving both 
 prescription and adherence of medicines regimens.  One of its aims is to 
 improve integrated care through better multi-professional working and with a 
 particular work stream utilising the role of the pharmacist. 
 
 Scottish Government will explore development of a system to improve and 
 enhance pharmacists’ role in working in partnership with patients and carers 
 to improve co-production and support self-management using mobile 
 technology. 
 
2.4 Therapeutic Partnerships & New Models of Working 
 
2.4.1 Sir Professor Lewis Ritchie’s report for Scottish Government on Establishing 
 Effective Therapeutic Partnerships18 discussed the importance of partnership 
 working between GPs and Pharmacists to deliver pharmaceutical care.  Key 
 themes identified in this report such as managing long term conditions and 
 services to care homes, are all reflected in the Wilson and Barber report, the 
 Vision and this Action Plan.  As the number of other prescribers such as 
 nurses, midwives and allied health professionals increases, it will be important 
 to form collaborative working relationships with these professionals as well as 
 GPs.  
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Scottish Government will seek to further enhance therapeutic partnerships 
which will be essential to embedding partnership working between the patient 
(or carer), their GP and pharmacist and other health and social care 
professionals. 
 
2.4.2 A recent study for the General Medical Council (GMC)19 suggests that around 
 one in eight patients have prescribing or monitoring errors, involving around 
 one in 20 of all prescription items.  As is common with errors, the vast majority 
 had no effect, or only a mild or moderate, effect.  However, one in 550 items 
 was associated with a serious error.  Some factors that increased the 
 probability of an error were the patient’s age (<15, >64) and the number of 
 items prescribed.  Monitoring errors (failure to monitor for the adverse effects 
 of certain medicines) tended to have more serious consequences than 
 prescribing errors.  The most frequent forms of prescribing error were 
 ‘incomplete information on the prescription’ and ‘dose/strength errors’.  The 
 most common monitoring error was ‘failure to request monitoring’ (69%).  In 
 care homes20 errors were more frequent where 39% of residents had one or 
 more prescribing errors. 
 
2.4.3 Specific problems have also been identified with the transfer of information at 
 the primary/secondary care interface. 
 
2.4.4 Many of the problems associated with medicines can be addressed though 
 effective therapeutic partnerships, including initiating medication, detecting 
 prescribing and monitoring errors. Involving patients in decision making 
 improves adherence and reduces waste.  Pharmacists working directly with 
 GPs can significantly contribute to addressing issues with prescribing21.  To 
 be effective,  pharmaceutical care requires good communication and shared 
 understanding with patients and local prescribers. Being focussed on the 
 outcome of interventions rather than the nature of them can equally be 
 applied to self-care, and to health promotion and prevention.  In the case of 
 self-care and self-management, the pharmacist will distinguish the complaints 
 that require referral to a doctor and those that can be dealt with by             
 self-medication, and provide appropriate advice and follow up. 
 
2.4.5 The Audit Scotland report 22 on prescribing in general practice highlighted the 
 beneficial effect of partnership working between GPs and pharmacists and 
 among its recommendations was to increase the access of pharmacist 
 support to GP practices.  This would be facilitated by creating clinical practice 
 models that would support this approach. 
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2.4.6 A particularly important role for pharmacists working with GPs to undertake is 
 polypharmacy and medication reviews to improve patient outcomes and 
 reduce harm through improving patient safety and effectiveness of 
 prescribing.  Last year, the Royal College of General Practitioners and the 
 Royal Pharmaceutical Society published a joint statement on partnership 
 working “Breaking down the barriers – how pharmacists and GPs can work 
 together to improve patient care”23.  This emphasises the complementary 
 roles of pharmacists and GPs in patient care, the value of collaborative 
 partnership, and the importance of professional learning together. 
 
Scottish Government will seek to further enhance the role of NHS accredited 
clinical pharmacist independent prescribers to work with GPs to deliver 
medication/polypharmacy review, using telehealthcare and domiciliary visits 
where appropriate. 
 
2.4.7 In order to deliver closer ways of working between GPs and pharmacists and 
 social care providers, new models and ways of working will be required. GPs 
 and pharmacist will work in collaboration to allocate caseloads to pharmacists 
 for management of patients with long term conditions. 
 
2.4.8 The European Active and Healthy Ageing Innovation Partnership recognises 
 the need to increase the pharmacist’s role in improving the health of the older 
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“I have had the privilege of working closely with Colin, a pharmacist colleague 
for many years. Initially starting from a relationship where he was 
always available for prescribing support from within his community pharmacy, 
through support within the practice as a prescribing support pharmacist, to now 
where he is a non medical prescriber running clinics both within and out with the 
practice on a shared care programme, initially for patients with hypertension and 
more recently for chronic pain control. Over this time I have come to more 
fully appreciate the significant role that a pharmacist colleague can play 
in working with GPs practices to deliver an enhanced level of care. It feels at 
times that we have the benefit of an 'attached pharmacist' such that we now 
regard him as a fully paid up member of our primary care team.” 
 
GP, Deep End Practice, Greater Glasgow and Clyde 






2.5 Continuity of NHS Pharmaceutical Care and the ‘Named Pharmacist’ 
 
2.5.1 Evidence gathered from the Wilson and Barber Review found that patients 
 wanted to know that they could develop a relationship with their pharmacist 
 and they expressed a preference to see the same pharmacist on a regular 
 basis. 
 
Scottish Government will explore the utilisation of caseloads to named 
pharmacists to contribute to the clinical management of Long Term Conditions 
by developing the concept for registration with a ‘named pharmacist’ for all 
pharmaceutical care needs throughout the patient journey. 
 
2.6  Anticipatory Care and Public Health 
 
2.6.1 An Audit Scotland report on Health inequalities24 found that there was a good 
 distribution of pharmacies across deprived communities in Scotland.  This will 
 enable the further development of accessible services for substance misuse, 
 including: drugs and alcohol, smoking cessation; sexual health as well as 
 early intervention for prevention of cardiovascular diseases. 
2.6.2 The Pharmore pilots25 offered a convenient access to a mix of primary care 
 service such as pharmacist led minor illness clinic and nurse-led minor injury 
 clinics available during normal pharmacy hours and in some cases extended 
 to include out of hours periods such as evenings and weekends and the work 
 undertaken in England by a collaborative of pharmacies demonstrated that up 
 to 60% of pharmacist consultations saved patients contacting a GP.  The 
 pilots have also reduced the need to access out of hours service.  Recent 
 data from NHS 24 indicates that more people are accessing pharmacy 
 services out of hours.  Using pharmacist prescribers would allow treatment of 
 common clinical conditions such as urinary tract infections and cystitis. 
 
Scottish Government will consider further development of the pharmacist’s 
contribution to the management of common clinical conditions and develop 
new models of delivery of primary care services in partnership with GPs. 
 
2.6.3 Our work programme will place increased focus on prevention, anticipatory  
 care and early intervention.  It will develop pharmaceutical care for specific 
 patient groups and specialist services: older people, mental health, children 
 and substance misuse. 
 
2.6.4 These arrangements are pivotal to the long term strategy to move 
 pharmacists away from a focus purely on the dispensing of medicines to the 
 provision of person- centred care as part of the wider healthcare team. 
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2.6.5 Together these services are an important part of the pharmacist’s contribution 
 in shifting the balance of care by: 
 
 improving access for the public as they do not need an appointment to see 
their pharmacist for a consultation; 
 decreasing unnecessary workload on the GP therefore freeing up their 
time to see patients with more serious complaints; 
 improving health outcomes and minimising adverse events from 
medicines; 
 helping to address health inequalities; and  
 making better use of the workforce by more fully utilising the skills of 
pharmacists. 
 
2.7 National NHS Specifications and Standards for Pharmaceutical Care 
 Services 
2.7.1 As services are developed, standards and specifications will need to be 
 developed to ensure consistency of service for patients and delivery of 
 outcomes that are person-centred. 
 
Scottish Government will develop with the professions new NHS standard 
specifications for services and innovative pharmaceutical care for specific 
patient groups. 
 
2.7.2 Areas that will be considered as a priority are the pharmaceutical care that is 
 delivered to people who are residents in care homes and those that are being 
 supported by social work or family to live at home.  A report from Reshaping 
 care for older people26 and the Royal Pharmaceutical Society’s report on 
 Improving Pharmaceutical care for patients in care homes27 highlight areas of 
 good practice for work in care homes across Scotland and also collaborative 
 working with social care. 
 
2.7.3 The polypharmacy guidance 28 published last year provides guidance on 
 undertaking reviews and outcome data for reviews that have been undertaken 
 for people taking medicines that are high risk.  National tools for monitoring 
 improvement and facilitating multi-disciplinary working will be further explored 
 with NES, Health Improvement Scotland (HIS) and Information Services 
 Division (ISD). 
 
2.7.4 Hospital at home is where some medicines which previously were only able to 
 be administered in the hospital setting are now given to patients in their own 
 home due to advances in technology and medicine design.  These are 
 prescribed by hospital consultants and supported by hospital pharmacists.  
 Hospital clinical pharmacists who are recognised as experts in medicines and 
                                               
26
 Reshaping Care for Older People: A Programme for Change, Scottish Government, 2012 
27
 Improving Pharmaceutical Care in Care Homes, Royal Pharmaceutical Society Scotland, March 
2012 
28
 Circular CEL 36 (2012), Appropriate prescribing for patients and polypharmacy guidance for review 
of quality, safe and effective use of long- term medication, Scottish Government, November 2012 





 are an integral part of the multidisciplinary ward clinical team in hospital. 
 These hospital pharmacists would be required to deliver pharmaceutical care 
 in the hospital at home setting to ensure continuity of pharmaceutical care.  
 
Scottish Government will develop new pharmaceutical care service models for 
hospital at home with medical, pharmaceutical professions and the 
pharmaceutical industry. 
 
2.7.5 Some other areas where national specifications and NHS standards will be 
 explored include smoking cessation, sexual health and drug and alcohol 
 services.  It is also well documented that people that abuse alcohol and drugs 
 are a high risk population.  They are well served in the provision of medicines 
 to treat their problems, but expansion of pharmacist prescribing skills to 
 review these medications is recommended.  
 
The Expert Group Review of Opiate Replacement Therapies29 (and substance 
misuse services) will be used to inform development of further services 
building on existing work already taking place in some NHS Boards. 
 
2.8 Stratified Medicine 
2.8.1 The landscape of therapeutics is presently undergoing revolutionary change 
 through the introduction of biopharmaceuticals and genomic research. This 
 rapidly developing field is producing new healthcare interventions through 
 translational genomics.  This in turn will create better drugs, improved insight 
 into the disease process and better diagnostic methods.  This whole new area 
 of therapeutics will place new demands on pharmaceutical care.  The 
 healthcare professions and academia need to quickly become more familiar 
 with this if patients are to fully benefit from this aspect of therapeutics.  This is 
 starting to be addressed in Scotland with the Scottish Government’s Chief 
 Scientist’s Office and the contribution of innovative pharmaceutical care will 
 need to be developed as will the education and skills of clinical pharmacists in 
 this area.  
 
2.8.2 Stratified medicine is a developing concept where genetic phenotype 
 modelling using genetic analysis of patients’ likelihood of benefiting from 
 particular drugs will allow for more specific targeting of drug treatment. 
 
Scottish Government will develop innovative pharmaceutical care to support 
the clinical application of translational genomics and stratified medicine. 
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Our work programme to deliver PERSON CENTRED 








1. Create a model to facilitate NHS accredited clinical 
pharmacist independent prescribers working in 
partnership with patients, GPs and other 
prescribers 
 
2. Introduce the utilisation of clinical case load for 
review and management of Long Term Conditions 
and prescribing through Therapeutic Partnerships 
e.g. polypharmacy and medication review 
 
3. Develop models to ensure all patients have 
pharmaceutical care including polypharmacy/ 
medication reviews where appropriate 
 
4. Work with the rural practitioners to scope and 
develop the use of domiciliary visits/ telehealth/ 
mobile apps to respond to needs of different age 
groups, and different settings 
 
5. Work with patients, professions to develop a NHS  
framework for registration with a ‘named 
pharmacist’ and implement the legislative and 
contractual framework to underpin this innovative 
approach 
 
6. Establish a framework for anticipatory 
pharmaceutical care planning 
 
7. Develop service models for those receiving high 
risk and high tech medicines building on risk 
assessment tools developed for polypharmacy and 
anticipatory care planning 
 
8. Scottish Government will develop innovative 
pharmaceutical care to support the clinical 









































































Our work programme to deliver PERSON CENTRED 








9. Develop national service with the professions new 
standard specifications for services and innovative 
Pharmaceutical care and pharmaceutical public 








Alcohol and Substance Misuse    
 







10. Further develop the pharmacists contribution to the 
management of common clinical conditions and 
develop new models of delivery of primary care 





































































  Chapter 3    Safety in pharmaceutical care and medicines 
 
 
In this Chapter we will set out our aims and related 
work programme to deliver safety in pharmaceutical 
care and medicines.  This will focus on developing 
approaches to: 
 
 Review of the governance arrangements for 
 the safe delivery of pharmaceutical care and 
 use of medicines in the community. 
 
 Implementing clinical guidelines and 
 Monitoring of the use of Medicines. 
 
 Implementing Scottish Patient Safety & 
 medicines reconciliation Programme across 
 pharmacy practice in primary care & 
 secondary care. 
 
 Introducing patient level risk assessments. 
 
 Introduce a framework for the use of patient 
 identifiable prescribing data to monitor 
 changes in prescribing. 
 
 Extend access to patient information systems 
 and enable the sharing of information between 
 pharmacists, GPs and other healthcare and 
 social care practitioners. 
 
  Establish a Performers List for pharmacists to 
      provide NHS Pharmaceutical Care.  All  
      pharmacists delivering clinical services will be 







services so that 
NHS 
pharmaceutical 
care is delivered in 
a safe 
environment 
preventing injury or 
harm to people 
from medicines, 
advice and support 





3.1 Introduction  
3.1.1 Safety in pharmaceutical care and medicines is uppermost in ensuring 
 optimum benefit from the therapy patients receive.  Building on our quality 
 ambitions, this Chapter will focus on our actions/strategy to help ensure that 
 there will be no avoidable injury or harm to people from medicines, or 
 from the advice or support they receive, and an appropriate, clean and safe 
 environment will be provided for the delivery of healthcare services at all 
 times. 
 
3.1.2 A study undertaken for the Royal Pharmaceutical Society of Great Britain30 
 found 3.3% dispensing errors, 5% of medicines prescribed at outpatient 
 appointments not added to GP records (13% of consultations were not added 
 to GP records).  In hospital they also found 18-60% discrepancy in medication 
 with 1.5-9.2% prescribing errors, and 11% discrepancy in discharge 
 medication.  Using NHS accredited clinical pharmacists in the community to 
 support medicines reconciliation as patients move between different care 
 settings will improve care and safety for patients. 
3.1.3 The Public Bodies (Joint Working)(Scotland) Bill to integrate adult health and 
 social care services is currently before Parliament and is designed to integrate 
 health and social care.  This Action Plan recognises the importance of 
 delivering NHS pharmaceutical care to recipients of local authority community 
 care services in a way which best meets the needs of those individuals.  This 
 is entirely consistent with the integration agenda.  If passed by Parliament in 
 its current form, the Public Bodies (Joint Working)(Scotland) Act will require 
 Health Boards and local authorities to work together to plan the delivery of 
 certain functions within their area and it is envisaged that this would include 
 the delivery of pharmaceutical care services in care homes.  Within care 
 homes, consistent clinical input from suitably qualified NHS accredited 
 pharmacist prescribers is recommended, working in partnership with GPs, 
 nursing and social work staff, patients and their carers to ensure appropriate 
 clinical governance in reviewing prescribing.  The same would apply for 
 patients living in their own homes with supported care.  It will be essential to 
 ensure that there is consistency of service standards for delivery. 
 
3.1.4 The Vision and Action Plan proposes that it is essential that NHS Boards 
 ensure all patients have access to NHS pharmaceutical care from a 
 pharmacist so that where the population is served by a dispensing doctor then 
 clinical pharmacist input is also available to the population.  Pharmacists 
 delivering this would need to be prescribers and on a NHS Board’s NHS 
 Pharmaceutical Care Performers List like other healthcare professionals in 
 primary care to ensure standards of care. 
 
3.1.5 The Vision sets out to address key issues highlighted in the Francis report31 
 such as patient safety and consistency and quality of care. 
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3.2 Governance arrangements for the safe delivery of pharmaceutical care  
 
3.2.1 The pharmacists that will be delivering the pharmaceutical care in the 
 community will need to ensure that when they manage patients, they work 
 with medical and nursing colleagues to implement clinical guidance and 
 undertake the relevant monitoring where appropriate.  They will need to 
 ensure they work closely with the NHS Board’s governance structure for 
 utilisation of medicines.  
 
Scottish Government will consider approaches to implementing clinical 
guidelines and monitoring of the use of medicines in all care settings. 
 
3.2.2 The development of new medicines is essential for advancing therapeutics.  
 This is a dynamic process which aims to improve clinical responses, whilst 
 reducing harm and/or side effects.  However, not all new medicines represent 
 a significant improvement over existing medicines in the same therapeutic 
 class. 
 
3.2.3 Medicines are the most common intervention in healthcare. The Audit 
 Scotland Report on Prescribing in General Practice suggests that 
 NHSScotland spends close to £1.4bn a year on medicines.  Of this 
 expenditure, almost £1bn (70%) is spent on medicines dispensed in primary 
 care. Territorial NHS Boards spend around 10% of their budgets on GP 
 prescribed medicines.  NHS clinicians have evolved processes such as Area 
 Drug and Therapeutics Committees (ADTCs) and the Scottish Medicines 
 Consortium (SMC) to ensure that the medicines they use represent value for 
 money. 
 
3.2.4 The ADTC functions support and help deliver the three quality ambitions, 
 particularly around patient safety and provision of the most appropriate 
 treatments at best cost.  SMC accepted medicines are considered by local 
 ADTCs for inclusion on their formularies. 
 
Scottish Government will consider the review of the clinical governance 
arrangements for the safe delivery of pharmaceutical care and use of 
medicines in the community.  
 
3.3 Scottish Patient Safety Programme 
3.3.1 The Scottish Patient Safety Programme (SPSP) has started to be delivered in 
 GP practices after the implementation in hospital settings.  The programme of 
 work for SPSP is now looking to extend utilising the role of pharmacists in 
 primary care.  Medicines reconciliation for patients post discharge would be 
 an important development in this area.  In addition, the review of high risk 
 medicines is intended to complement the patient safety agenda in GP 
 practices and will see inclusion of more high risk medicines.  It is important to 
 acknowledge that appropriate review of prescribing at medication review, 
 which may or may not be to address polypharmacy should address many of 
 the safety issues as highlighted in CEL 36 (2012). 





Scottish Government will develop approaches to implement Scottish Patient 
Safety & Medicines Reconciliation Programme across pharmacy practice in 
primary care & secondary care. 
 
3.4 Patient Level Risk Assessments  
3.4.1 Patient risk assessment tools have been developed to identify people that 
 would most benefit from interventions to ensure safe and appropriate 
 prescribing.  This approach has been applied to target polypharmacy reviews 
 but also in Change Fund initiatives where enhanced pharmaceutical care has 
 resulted in improved outcomes for older people including prevention of 
 readmission.  Patient support tools can also be used to help support 
 adherence32.  This is important as discussed above it is estimated that up to 
 50% of drugs are not taken as prescribed. 
 
Scottish Government will develop approaches to introducing patient level risk 
assessments for patients taking medication. 
 
3.5 Patient Identifiable Prescribing Data 
 
3.5.1 Patient identifiable data allows appropriate monitoring of high risk prescribing.  
 It can be used to measure improvements in prescribing and potentially 
 improves patient safety.  Work has started with NHS Scotland Information 
 Services Division (ISD) to build indicators that can be used by GPs and 
 pharmacists.  This data also helps improve evidence based prescribing.  As 
 part of the Vision, all pharmacists working with GP practices would be given 
 appropriate skills to use prescribing data.  Currently this role is undertaken by 
 prescribing advisors but as the Audit Scotland report recommends, there is a 
 need to increase the pharmacist and analytical input to practices across 
 Scotland. 
 
3.5.2 The development of data sets with time should also allow for the monitoring of 
 treatments in different patient groups and this should be governed by Area 
 Drug & Therapeutic Committees.  
 
Scottish Government will develop approaches to introduce a framework for 
the use of patient identifiable prescribing data to monitor patterns and 
changes in prescribing. 
 
3.6 Patient Information Systems 
 
3.6.1 In order to deliver safe and effective care, the Vision proposes that 
 pharmacists providing clinical care would be given access to relevant clinical 
 data to ensure medication and care issues can be managed appropriately.  
 Access to electronic Key Information Summary eKIS and Emergency care 
 summaries (ECS), as well as sharing relevant information with social care and 
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 other health colleagues will be essential, as more patients with complex and 
 changing support needs are managed at home. 
 
3.6.2 Pilot work is almost complete in three NHS Boards to develop the Hospital 
 Pharmacy Care Record (HPCR) and sharing of the existing Pharmacy Care 
 Record (PCR) in the community as the individual moves between different 
 care settings.  This is of benefit as the information generated from the  
 pharmacy shows what medicines the patient actually collects as opposed to 
 what is prescribed.  Sharing of information on patient discharge with 
 pharmacists means that the rationale for changes in medication can be 
 understood and implemented safely at this point. 
 
Scottish Government will develop approaches to extending access to patient 
information systems and enable the sharing of information between 
pharmacists, GPs and other healthcare and social care practitioners. 
 
3.7 NHS Pharmaceutical Care Performers List  
3.7.1 Many primary care health professionals such as GPs and dentists have 
 performers lists that are held with the local NHS Board.  The Wilson and 
 Barber Review recommends the introduction of a performers list (for 
 pharmacists working in the community) that will underpin the principles of 
 fitness to practice, professional good standing, professional standards and 
 clinical governance which will improve safety for patients. 
 
3.7.2 When designing services and introducing change, the design should allow for 
 minimal disruption to the workflow33, therefore, working in collaboration with 
 GPs, pharmacist independent prescribers will be able to implement change 
 for patients without increasing the work burden for other healthcare 
 professionals. Pharmacists will be supported to develop their skills so that 
 they will be able to work as independent prescribers. 
 
Scottish Government will develop approaches to establishing a Performers 
List for Pharmacists who provide NHS Pharmaceutical Care. 
 
3.7.3 Pharmaceutical care planning that takes place at NHS Board level should 
 help inform workforce planning, education and training. 
 
  
                                               
33 Bohmer, R. M, Designing Care. Boston: Harvard Business Press, 2009. 
 





Our work programme to deliver SAFE 





Years   
5-10 
 
1. Review of the governance arrangements for the 
safe delivery of pharmaceutical care and use of 
medicines in the community  
 
 
2. Implementing clinical guidelines and Monitoring 
use of Medicines 
 
 
3. Establish partnerships with HIS, and the 
professions to mainstream the aims of the 
Scottish Patient Safety Programme in pharmacy 
and medicines practice 
 
 
4. Develop and implement a framework for the 
appropriate use of patient identifiable prescribing 
data and risk assessment 
 
 
5. Work with health professionals to enhance shared 
clinical patient information systems to support 
pharmacists providing clinical care 
 
 
6. Develop with the professions NHS Pharmaceutical 
Care Performers list for patient registration to 

























































   Chapter 4     Effectiveness of pharmaceutical care and medicines 
 
In this Chapter we will set out our aims and related 
work programme to deliver effectiveness of 
pharmaceutical care and medicines. This will focus on 
developing approaches to: 
 
 Define and implement a robust framework of 
 NHS Board Pharmaceutical Care Services Plans 
 informed by a local needs assessment. 
 
 NHS Boards identifying clusters of pharmacists 
 that could work as a group. 
 
 Introduce general practice clinical pharmacists 
 working in primary care who are pharmacists 
 delivering pharmaceutical care in the
 community. 
 
 Redesign the dispensing process to be 
 effective and efficient, releasing pharmacists’ 
 time for clinical care through workforce 
 planning and improved use of pharmacy team 
 and automation using robotics. 
 
 Further development of models to reduce 
 harmful and wasteful variation in prescribing. 
 
 Implement contracts, models and/ or service 
 frameworks to prevent perverse incentives that 
 compromise professionalism. 
 
 
 Ensure clinical and cost effective use of existing, new medicines and 
technologies by implementing evidence based guidance through Area Drug 
and Therapeutics Committees. 
 
 Design models for provision of hospital Homecare medicines co-ordinated 
through integrated working between hospital and community pharmacists 
and pharmaceutical industry. 
 










provided at the 
right time reducing 
waste, harm and 
variation and 
ensuring clinical 
and cost effective 
use of both 
existing and new 
medicines and 
technologies 







4.1.1 There are a number of workforce issues including the fact that, currently, the 
 skills of a pharmacist are underutilised in the community setting.  More 
 effective pharmaceutical care can be delivered by allowing the pharmacist to 
 develop their professional clinical skills.  Medicines arrive at the pharmacy 
 mostly pre-packed. With the exception of the clinical check being undertaken 
 by the pharmacist, the dispensing process could be managed by appropriately 
 qualified technicians, thereby releasing pharmacists’ time to undertake 
 pharmaceutical care in the most appropriate setting, which may be the GP 
 practice or the person’s home. 
 
4.1.2 NHS Board Pharmaceutical Care Services Plans will identify the 
 pharmaceutical needs for their populations, and also the clusters of 
 pharmacists that could work collaboratively together to deliver clinical care as 
 a group practice. 
 
In order to deliver effective pharmaceutical care, it is essential that the 
most appropriate treatments, interventions, support and services will be 
provided at the right time to reduce wasteful or harmful variation. 
 
4.2 NHS Board Pharmaceutical Care Services Plans  
4.2.1 This will be central to how NHS Scotland plans, provides and delivers 
 pharmaceutical care and medicines to its communities.  In the longer term it 
 has implications for existing arrangements for service provision, where and  
 how it is provided. These plans will need to consider population needs, which 
 include public health and health inequalities.  
 
4.2.2 NHS Boards are responsible and accountable for the provision of 
 pharmaceutical services in secondary and primary care sectors.  Currently in 
 primary care, NHS Boards make arrangements with pharmacy owners for the 
 delivery of pharmaceutical services.  The pharmacist delivering these services 
 needs to ensure that their priorities are focused on the patient above all else.  
 Perverse incentives such as targets and bonuses based on commercial retail 
 priorities should not be allowed to adversely affect patient care.  
 
4.2.3 More importantly, NHS Board Pharmaceutical care planning will facilitate the 
 clustering of pharmacists to deliver pharmaceutical care for patients without 
 decreasing the accessibility of a pharmacy services to a community. In 
 addition, it may be appropriate for secondary care pharmacists and those 
 working in primary care to work collaboratively together to deliver homecare 
 medicines or hospital at home clinical pharmacy services where complex or 
 specialised medicines are being taken.  It is recognised that this is a 
 fundamental shift in approach which we will consult on as appropriate. 
 
4.2.4 The provision of pharmaceutical care out of hours will be reviewed with 
 NHS 24. 
 





Scottish Government will explore defining and implementing a robust 
framework of NHS Board Pharmaceutical Care Delivery Plans informed by a 
local needs assessment, and work with NHS Boards to identify clusters of 
pharmacists that could work as a group, and introduce contracts or service 
frameworks which prevent perverse incentives. 
 
4.2.5 In some parts of rural Scotland, the NHS relies on dispensing doctors to 
 provide dispensing services to their own patients who (through geography and 
 demographics) are unable to secure the dispensing services of a community 
 pharmacy.  In these cases we will need to explore how these patients can be 
 supported in terms of pharmaceutical care. 
 
Scottish Government will work with patients, dispensing doctors and 
appropriate stakeholders to explore how rural communities can be further 
supported in terms of pharmaceutical care. 
 
4.3 The General Practice Clinical Pharmacist 
4.3.1 The vision of all patients having access to NHS pharmaceutical care from 
 clinical pharmacist independent prescribers in all settings will be achieved 
 though extending and developing the clinical pharmacy services currently 
 provided by pharmacist prescribers in both community and secondary care.  
 In order to rapidly expand the provision of pharmaceutical care in the 
 community, the concept of the “general practice clinical pharmacist” will be 
 considered.  The skills of appropriately qualified hospital, primary care and 
 community pharmacists can be harnessed to form the foundation of the 
 general practice clinical pharmacist.  This will begin to plug identified gaps in 
 the provision of pharmaceutical care, and to target the most vulnerable and 
 high risk patient groups.  We will consider the advancement of pharmacists’ 
 skills that will also be required to be developed.  Examples include prescribing 
 in clinics and polypharmacy review for the frail elderly and those in care 
 homes, and monitoring outcomes with medicines. 
 
Scottish Government will establish with NHS, NES and professional bodies 
the framework for development of general practice clinical pharmacists. 
 
 
4.4 Release Time for Pharmacists to Deliver Pharmaceutical Care 
 
4.4.1 In order for pharmacists to deliver the effective pharmaceutical care required, 
 work force planning and redesign will be required to use the available skills of 
 the workforce. In particular, the use of pharmacy technicians and pharmacy 
 assistants should help to facilitate this.  
 
4.4.2 Consideration would also need to be given to the automation of the supply of 
 medicines using robotics and routine repeat dispensing transferred to serial 
 dispensing.  It is important to build in here a patient information system that 
 would allow sharing of electronic data across primary and secondary care and 
 implement a paperless integrated electronic prescribing system. 





Scottish Government will consider redesign of the dispensing process to 
release time for clinical care using workforce planning, improved use of 
pharmacy team and robotics. 
 
4.5 Reduce Harmful and Wasteful Variation in Prescribing 
4.5.1 The prescribing work stream of the NHS Scotland Efficiency & Productivity 
 Framework has started to develop tools for clinicians to address harmful and 
 wasteful variation in prescribing.  The York University report into waste34 
 identified that medication review was an appropriate way to address waste.  
 Development of indicators to illustrate variation in prescribing with appropriate 
 clinical guidelines is an effective way to change behaviour.  The PINCER trial  
 was a randomised controlled trial that demonstrated that pharmacists working 
 with GPs provided better outcomes than just sharing electronic data. 
 
Scottish government will explore extending joint working of pharmacist with all 
other prescribers to ensure all patients have appropriate pharmaceutical care  
 
4.6 Integration of Primary and Secondary Care Pharmaceutical Care and 
 Medicines 
4.6.1 In order to deliver effective person-centred care, pharmaceutical care will 
 need to be delivered across the interfaces of health and social care.  
 Pharmacists will have a role in facilitating better integration of advice and use 
 of medicines across sectors and disciplines. 
 
4.6.2 Hospital at home is a developing concept where patients needing hospital 
 care are facilitated to live at home by providing hospital care in their own 
 homes and to be treated with medicines that would normally be given in a 
 hospital setting.  In order to deliver this effectively, pharmacists working in 
 hospital and primary care will need to work as a team, ensuring effective 
 sharing of information to improve patient safety. 
 
4.6.3 Pharmacy Homecare is where medicines prescribed by the hospital 
 specialists are delivered to patients in their own homes. It is proposed these 
 medicines should be delivered through NHS pharmaceutical care services to 
 allow capture of prescribing information for the patient and to assess 
 suitability and compatibility with other medications.  This would allow for 
 appropriate governance and monitoring.  By having a complete record of all 
 medications that a patient is taking adequate monitoring can be provided. 
 
Scottish Government will consider models for provision of hospital homecare 
medicines co-ordinated through integrated working between hospital and 
community pharmacists and pharmaceutical industry. 
  
                                               
34
 Evaluation of the scale, causes and costs of waste medicines, York Health Economics 
Consortium/School of Pharmacy, University of London, November 2010. 





4.7 Technology- Telehealthcare and Mobile Apps 
4.7.1 Effectiveness of delivery of pharmaceutical care may be enhanced by the use 
 of technology and mobile apps.  The national delivery plan for telehealth and 
 telecare considers technology as a tool to drive improvement and to facilitate 
 greater integration, skill mix, choice and control.  Use of technology would 
 allow pharmacists to effectively manage their case load of patients. 
 
4.7.2 The European Innovation Partnership in active and healthy ageing promotes 
 the use of mobile applications to enable people to self-manage, improve 
 adherence to treatment and to provide decision making support for 
 professionals.  These applications for mobile technologies are best developed 
 through collaboration between healthcare, and technology companies and 
 patient groups so that their effectiveness can be assessed. 
 
Scottish Government will introduce a framework to promote and increase the 
use mobile technology to support people manage their medications and 
improve adherence 
 
4.7.3 The Scottish Government Health and Innovation Partnership Board would 










Our work programme to deliver EFFECTIVE 





Years   
5-10 
 
1. Consult on the powers of NHS Board 
Pharmaceutical Care Plans and its impact on 
existing planning arrangements including 
dispensing doctors 
 
2. Establishing with NHS, NES and professional 
bodies the framework for development of general 
practice clinical pharmacist 
 
3. Develop new models to enhance role of pharmacist 
by better use of pharmacy workforce such as 
pharmacy technicians and pharmacy assistants 
 
4. Establish a framework of joint working and 
information sharing between primary and 
secondary care pharmacist and other members of 
the multidisciplinary team 
 
5. Redesign the dispensing process to release 
pharmacists time or clinical care through workforce 
planning and improved use of pharmacy team and 
automation using robotics  
 
6. Establish a public/private partnership framework to 
promote and increase the use of robotics 
 
7. Build on the work being taking forward through 
NHS Scotland Efficiency & Productivity programme  
 
8. Respond to Audit Scotland report into prescribing 
in general practice - in particular to extend joint 
working of pharmacist with all other prescribers to 
ensure all patients have appropriate 
pharmaceutical care  
 
9. Introduce a framework to promote and increase the 
use mobile technology to support people manage 













































































   Chapter 5          Making it Happen: Infrastructure to deliver 
pharmaceutical care 
 
In this Chapter we set out our aims and related work 
programme to develop the infrastructure that 
supports pharmaceutical care. This will focus on 
developing approaches to: 
 
 Ensure a workforce that is fit for purpose by 
 implementation of NHS standards of practice 
 for pharmaceutical care are attained through 
 working with the NHS, Schools of Pharmacy 
 and Medicine, NES and the professional and 
 regulatory bodies. 
 
 Ensure education and training meets the 
 needs of patients and the NHS. 
 
 Provision of NHS Clinical and Professional 
 Leadership. 
 
 Implement HEPMA to allow for electronic 
 capture of prescribing data in secondary care. 
 
 Develop and implement a modern framework 
 for planning NHS Pharmaceutical Care 
 Services. 
 
 Ensure that pharmacy premises are suitable 
 for the delivery of pharmaceutical care. 
 
 Support the use of action research, practice research 
and clinical research that enables development and 




















 Implementation of primary and secondary 
           care configured systems to allow electronic 
 information sharing contributing to 
 pharmaceutical care and electronic 
 prescribing for all prescribers including 
 pharmacist prescribers. 





5.1 Introduction  
 
5.1.1 In this Chapter we focus on how we will put in place the foundation blocks for 
 making our Vision and strategy happen from pharmacy practice development, 
 education, research and electronic sharing of information, to medicines supply 
 and premises. 
 
5.1.2 This Action Plan acknowledges the important and effective role that is played 
 by the network of pharmacies across Scotland in the provision of medicines 
 and access to healthcare advice. 
 
5.1.3 The legislation needed to reconfigure all aspects of how we plan, contract and 
 deliver NHS Pharmaceutical Care and Services will be considered. Particular 
 consideration will be given to the increased focus on the clinical aspects of 
 pharmaceutical care and how this might be delivered in the future. 
 
5.1.4 Prime responsibility for delivering the Vision locally will rest with NHS Boards 
 and their Directors of Pharmacy working with others, and will take into 
 account any new approaches resulting from the integration of health and 
 social care.   
 
5.2 Workforce, Education and Training 
5.2.1 The Vision proposes that pharmacists in 2020 would be released from routine 
 dispensing to work as NHS accredited clinical pharmacist independent 
 prescribers delivering pharmaceutical care.  In order to achieve this, the 
 Wilson and Barber report recommends developing a framework to ensure a 
 workforce that is fit for purpose to deliver pharmaceutical care for the            
 21st century, reviewing all aspects of pharmacy workforce and associated 
 education, training and professional attainments of standards.  There is 
 currently no central locus for pharmacy national workforce planning in 
 Scotland.  NHS Education for Scotland (NES), working with key stakeholders 
 such as the Schools of Pharmacy and the NHS Boards, should be 
 commissioned to undertake data collection and trend analysis to lead to better 
 supply and demand forecasting, and capacity planning for the pharmacy 
 workforce.  
 
5.2.2 In addition, by 2020, the accredited clinical pharmacists delivering 
 pharmaceutical care would need to be independent prescribers that would 
 work in partnership with GPs and have case loads to manage. 
 
5.2.3 The undergraduate pharmacy programmes in Scotland needs to ensure that 
 graduates are fit for the future requirements of the NHS with the right balance 
 of clinical, supervised practice and interdisciplinary experience, taking into 
 account future workforce needs of the NHS and the regulatory framework. 
 
5.2.4 Education and training in multidisciplinary team based practice at both 
 undergraduate and postgraduate level would be critical to develop more 
 collaborative methods of working.  This would be led by the Scottish 





 Government and NES, working in partnership with the Schools of Pharmacy 
 and Medicine in Scotland and professional and regulatory bodies. 
 
5.2.5 Work is already underway with a scoping exercise of what the educational 
 requirements of such an approach might be.  In addition, joint post-graduate 
 training is currently being facilitated by the relevant professional bodies. 
 
5.2.6 NES which currently administers and funds the Pre-registration Pharmacist 
 Scheme (PRPS) would work with the Scottish Government, Schools of 
 Pharmacy and the NHS to advance to a more integrated academic and 
 clinical undergraduate programme, including a planned and co-ordinated 
 supervised practice through undergraduate placements.  In addition, 
 consideration should be given to a NES Deanery structure for pharmacy 
 similar to medicine to enhance educational quality assurance and appropriate 
 training environments for the future pharmacy workforce. The quality 
 management of the learning environment of both placement and the pre-
 registration year for pharmacy trainees, including formal tutor appraisal, could 
 be assumed by NES, in line with other professional groups in the NHS. 
 
5.2.7 A significant part of formal post-graduate training is focused on hospital based 
 pharmacists, linking to potential career development. This needs to be further 
 developed into a structured career framework for hospital and community 
 pharmacists which introduces NHS accredited clinical pharmacist 
 independent prescribers and also accommodates other new and innovative 
 models of practice. Further consideration should be given to how the      
 newly-launched Royal Pharmaceutical Society (RPS) Faculty for Professional 
 Career Assessment could support the NHS to facilitate a robust career 
 framework suitable for the needs of the NHS in Scotland. 
 
Scottish Government will establish an early review of all aspects of pharmacy 
workforce and associated education and training involving NES, Schools of 
Pharmacy, Schools of Medicine, NHS Boards and the professional and 
regulatory bodies to develop an integrated approach to ensure a workforce 
that is fit for purpose and that meets the future service needs of NHSScotland.  
 
5.3 Clinical and Professional Leadership 
 
5.3.1 The provision of NHS pharmaceutical care is the responsibility of the NHS 
 Board working with the Scottish Government.  NHS Boards would take the 
 lead in creating professional and clinical networks to support all pharmacists 
 providing care to the NHS patients.  These would need further strengthening 
 through professional recognition and identification of professional leaders and 
 clinical leaders within each NHS Board.  This will be supported by NES, HIS 
 and the professional and regulatory bodies.  These leaders should also work 
 with pharmacy owners and employers of pharmacists to ensure a common 
 understanding of the importance and requirement of the professionalism of 
 individual pharmacist and the creation of systems to support this.  





Scottish Government will work with NES, HIS and professional and regulatory 
bodies to develop Clinical and Professional Leadership in a multi-disciplinary 
environment. 
 
5.4  eHealth and Technology 
 
5.4.1 eHealth plays a vital role in enabling some of the key activities set out in this 
 Pharmaceutical Care Action Plan. 
 
5.4.2 The eHealth Strategy 2011-17 provides the strategic direction for eHealth, 
 with the principles of service-led change, joint governance and incremental 
 development at its heart. eHealth in NHSScotland also provides a governance 
 framework for technology developments, ensuring that products and 
 approaches deliver solutions that enable and support person-centred, safe 
 and effective practice. It also ensures that investments in IT are based on the 
 principle of convergence, are flexible and have the ability to integrate easily. 
 
5.4.3 A core set of technology products and services have been widely adopted 
 across pharmaceutical services.  However, the major technology solutions 
 that are currently in place to support pharmaceutical care across 
 NHSScotland are not fully integrated at this time.  In addition, in secondary 
 care, Hospital Electronic Prescribing and Medications Administration 
 (HEPMA) and related electronic decision support has only been implemented 
 in a very small number of acute hospitals, and in those cases not to its full 
 potential. 
 
5.4.4 Evidence from the Wilson and Barber Review recommends the increased use 
 of robotic dispensing due to benefits in reducing dispensing errors, better use 
 of workforce and better sharing of electronic patient data. 
 
5.4.5 Sharing of relevant electronic patient data, for case management, is 
 considered to be critical to ensuring delivery of pharmaceutical care both 
 within primary care but also across secondary care.  In order to optimise 
 patient safety and to allow for appropriate monitoring of prescribing 
 appropriateness and safety, electronic prescribing and sharing of information 
 between primary and secondary care would need to be in place in all NHS 
 Boards.  
 
Scottish Government will develop approaches to implement primary and 
secondary care electronic prescribing configured systems to allow electronic 
information sharing that contributes to pharmaceutical care for all prescribers 
including pharmacist prescribers. 
 
5.4.6 The eHealth strategy’s aims are to use information and technology in a 
 coordinated way to: 
 
 maximise efficient working practices, minimise wasteful variation, bring 
about measurable savings and ensure value for money. 





 support people to communicate with the NHS in Scotland, manage their 
own health and wellbeing; to become more active participants in the care 
and services they receive. 
 contribute to care integration and to support people with long term 
conditions. 
 improve the availability of appropriate information for healthcare workers 
and the tools to use and communicate that information effectively to 
improve quality, and develop an approach to a Single Virtual Medications 
Care Record. 
 improve the safety of people taking medicines and their effective use 
including the development of medications and related standards. 
 to provide clinical and other local managers across the health and social 
care spectrum with the timely management information they need to 
inform their decisions on service quality, performance and delivery. 
 
5.4.7 Activities that underpin these six aims will have an impact on the delivery of 
 the Pharmaceutical Care Action Plan, but the fifth aim in particular focuses on 
 the safety and effectiveness of pharmaceutical care, irrespective of the 
 setting. 
 
Scottish Government will consider roll out of HEPMA to allow for electronic 
capture of prescribing data in secondary care. 
 
5.5 Modern Framework for NHS Pharmaceutical Care  
 
5.5.1 To meet rising demands, the Vision places greater emphasis on the planning, 
 contracting and delivery of pharmaceutical care.  
 
We will develop the new framework and requirements of the future through 
consultation, modelling of different methods of working and evaluating pilots. 
 
5.5.2 The Wilson and Barber report recommends that essential to the delivery of 
 pharmaceutical care will be the suitability of premises to ensure that patients’ 
 privacy and confidentiality is safe guarded.  Pharmacy owners will need to 
 consider how this will be achieved. 
 
Scottish Government will work with patients and pharmacy owners to ensure 
that pharmacy premises are suitable for the delivery of pharmaceutical care. 
 
5.5.3 In order to release time to allow more care it will be important to optimise the 
 roles of the pharmacy team and automate dispensing where possible.  
 Telehealthcare is also considered to be an important tool to help reach more 
 patients, not just in remote and rural areas but also in urban settings. 
 





5.6 Action Research, Practice Research and Clinical Research 
 
5.6.1 It is important not only that any long term healthcare plan is based on 
 evidence where possible (or best practice where there is no evidence), but 
 also on pioneering and innovative practice which takes into account future 
 requirements.  This includes considerations of workforce, new technology, 
 changing demographics and increasing clinical demand.  This Action Plan is 
 built on all of these but, as Wilson and Barber concluded in their report, “it is 
 also important that any plan for future development has built into it measures 
 for success and methods of monitoring and evaluation, so that there is a clear 
 and demonstrable path for progress.” 
 
5.6.2 And so it is with this plan which demands new ways of thinking, new ways of 
 working and new models of care.  In testing these developments, therefore, it 
 is proposed that the plan proposed will be dynamic and supported and 
 informed by a programme of action, practice and clinical research: 
 
 Action research to inform and evaluate new ways of working and logistics 
 
 Practice research to examine new models of pharmaceutical care, 
partnership working, and patient and stakeholder satisfaction 
 
 Clinical research to assess the safety and effectiveness of new services 
in terms of clinical outcomes. 
 
5.6.3 This work would be undertaken in partnership with the Schools of Medicine 
 and Pharmacy in Scotland.  
 
Scottish Government will support the use of action based research, practice 
research and clinical research that enables development and evaluation of 
pharmaceutical care. 
 
5.7 Making it Happen – Implementation 
 
5.7.1 At the end of each chapter we have set out the main areas considered to 
 deliver the vision.  This work will be taken forward under a governance 
 structure in the Scottish Government Health Directorates to consider each of 
 the areas identified for development and to provide a detailed work 
 programme and delivery plans. 
 
  





Our work programme will explore options to 
provide INFRASTRUCTURE to deliver 
pharmaceutical care : 
Years   
1-3 
Years   
3-5 
Years   
5-10 
 
1. Establish an education and training framework 
to help pharmacists deliver pharmaceutical 
care to patients in all settings 
 
2. Develop and establish a framework for 
workforce development to ensure adequate 
resource to deliver the Vision of general 
practice pharmacists working in primary care 
 
3. A framework to support clinical and 
professional leadership 
 
4. Develop an integrated approach to deliver a 
Single Virtual Medications Care record 
available at each point of care 
 
5. Support the on-going development and 
introduction of medications standards 
 
6. Integrate and build on facilities already 
operational for the pharmacist-to-person 
registration service 
 
7. Develop technology for decision support in 
prescribing and dispensing 
 
8. HEPMA to allow for electronic capture of 
prescribing data in secondary care  
 
9. Develop, consult on, and implement a modern 
framework for planning, contracting and 
delivering NHS Pharmaceutical Care Services 
considering legislative changes that might be 



































































































 Chapter 6  Summary of key actions 
 







1. Create a model to facilitate clinical pharmacist 
prescribers working in partnership with patients, 
GPs and other prescribers 
 
2. Introduce the utilisation of clinical case load for 
review and management of Long Term Conditions 
and prescribing  through Therapeutic Partnerships 
e.g. polypharmacy and medication review 
 
3. Develop models to ensure all patients have 
pharmaceutical care including polypharmacy/ 
medication reviews where appropriate 
 
 
4. Work with the rural practitioners to scope and 
develop the use of domiciliary visits/ telehealth/ 
mobile apps to respond to  needs of different age 
groups, and different settings 
 
 
5. Work with patients, professions to develop a NHS  
framework for registration with a ‘named 
pharmacist’ and implement the legislative and 




6. Establish a framework for anticipatory 
pharmaceutical care planning 
 
 
7. Develop service models for those receiving high 
risk and high tech medicines building on risk 
assessment tools developed for polypharmacy and 
anticipatory care planning 
 
8. Scottish Government will develop innovative 
pharmaceutical care to support the clinical 

















































































9. Develop national service with the professions new 
standard specifications for services and innovative 
Pharmaceutical care and pharmaceutical public 








Alcohol and Substance Misuse    
 






10. Further develop  the pharmacists contribution to 
the management of common clinical conditions 
and develop new models of delivery of primary care 



































































Years   
5-10 
 
1. Review of the governance arrangements for the 
safe delivery of pharmaceutical care and use of 
medicines in the community  
 
2. Implementing clinical guidelines and Monitoring 
use of  Medicines 
 
3. Establish partnerships with HIS, and the 
professions to mainstream the aims of the 
Scottish Patient Safety Programme in pharmacy 
and medicines practice 
 
4. Develop and implement a framework for the 
appropriate  use of patient identifiable prescribing 
data and risk assessment 
 
5. Work with health professionals to enhance shared 
clinical patient information systems to support 
pharmacists providing clinical care 
 
6. Develop with the professions  NHS 
Pharmaceutical Care Performers list for patient 
registration to allow patients to  have appropriate 

























































Years   
5-10 
 
1. Consult on the powers of NHS Board 
Pharmaceutical Care Plans and its impact on 
existing planning arrangements including 
dispensing doctors 
 
2. Establishing with NHS, NES and professional 
bodies the framework for development of general 
practice clinical pharmacist 
 
3. Develop new models to enhance role of pharmacist 
by better use of pharmacy workforce such as 
pharmacy technicians and pharmacy assistants 
 
4. Establish a framework of joint working and 
information sharing between primary and 
secondary care pharmacist and other members of 
the multidisciplinary team 
 
5. Redesign the dispensing process to release 
pharmacists time or clinical care through workforce 
planning and improved use of pharmacy team and 
automation using robotics  
 
6. Establish a public/private partnership framework to 
promote and increase the use of robotics 
 
7. Build on the work being taking forward through 
NHS Scotland Efficiency & Productivity programme  
 
8. Respond to Audit Scotland report into prescribing 
in general practice - in particular to extend joint 
working of pharmacist with all other prescribers to 
ensure all patients have appropriate 
pharmaceutical care  
 
9. Introduce a framework to promote and increase the 
use mobile technology to support people manage 











































































INFRASTRUCTURE  to deliver pharmaceutical 
care  
Years   
1-3 
Years   
3-5 
Years   
5-10 
 
1. Establish an education and training    
framework to help pharmacists deliver 
pharmaceutical care to patients in all settings 
 
2. Develop and establish a framework for 
workforce development to ensure adequate 
resource to deliver the Vision of general 
practice pharmacists working in primary care 
 
3. A framework to support clinical and 
professional leadership 
 
4. Develop an integrated approach to deliver a 
Single Virtual Medications Care record 
available at each point of care 
 
5. Support the on-going development and 
introduction of medications standards 
 
6. Integrate and build on facilities already 
operational for the pharmacist-to-person 
registration service 
 
7. Develop technology for decision support in 
prescribing and dispensing 
 
8. HEPMA to allow for electronic capture of 
prescribing data in secondary care  
 
9. Develop, consult on, and implement a modern 
framework for planning, contracting and 
delivering NHS Pharmaceutical Care Services 
considering legislative changes that might be 





















































































Drivers for Change  
 
The Wilson and Barber Review was commissioned by Nicola Sturgeon MSP,  
Cabinet Secretary for Health, Wellbeing and Cities Strategy in October 2011.  The 
findings from this and other reports and studies have provided the evidence to 
support the Vision NHS Pharmaceutical Care for the future.  The main drivers for 
change are listed below: 
 
- Ambitions of 20:20 Vision - Achieving Sustainable Quality in Scotland’s 
Healthcare: A 20:20 Vision 2011, Scottish Government, September 2011. 
- A Route Map to the 2020 Vision for Health and Social care, Scottish 
Government, March 2013. 
- Healthcare Quality Strategy for NHSScotland - The Healthcare Quality 
Strategy for NHSScotland, Scottish Government, May 2010. 
- NHS healthcare as a whole is changing and needs to evolve to meet 
demographic changes, the associated changes in morbidity and continuing 
health inequalities.  
- Continuity of care was expressed as an important issue by the patient group. 
- Integration of health and social care 
- Desire to treat patients in their own homes/communities where possible 
- Evolution of therapeutics and new types of medicines e.g. stratified medicines 
- Desire for Scotland to be a leader in healthcare/patient safety/research 
- Increase in multi-morbidity and co-morbidity and resulting complex needs 
- Focus on adherence/non-compliance 
- eHealth Person-Centred Strategy.35 
 
 
                                               
35
 Person-centred eHealth Strategy and Delivery Plan, Scottish Government, 2012 





Appendix 2   
Evidence 
 
Alongside the Wilson and Barber Review, other key documents, reports and pilots 
have provided evidence for the development of the Vision, as follows:- 
 
 
- Breaking down the barriers – how pharmacists and GPs can work together to 
improve patient care, RCGP Scotland and RPS Scotland Joint Statement, 
2012. 
 
- Care homes' use of medicines study: prevalence, causes and potential harm 
of medication errors in care homes for older people, Barber ND, Alldred DP, 
Raynor DK, Dickinson R, et al. Quality and Safety in Health Care. 2009:341-6. 
 
- Establishing Effective Therapeutic Partnerships - A generic framework to 
underpin the Chronic Medication Service element of the Community 
Pharmacy Contract, Scottish Government, December 2009.- 
http://www.scotland.gov.uk/Publications/2010/01/07144120/0 
 




- The Future of Community Pharmacy: Building a Sustainable Industry, AT 








- Improving Pharmaceutical Care in Care Homes, Royal Pharmaceutical 
Society Scotland, March 2012. http://www.rpharms.com/promoting-pharmacy-
pdfs/rpscarehomereportfinalmarch2012.pdf 
 
- Investigating the prevalence and causes of prescribing errors in general 
practice: ThePRACtICe Study, A report for the GMC, Avery A, Barber N, 
Ghaleb M, Dean B et al, 2012. 
 
- A National Telehealth and Telecare Delivery Plan for Scotland to 2015: 
Driving Improvement, Integration and Innovation, Scottish Government, 
December 2012. http://www.scotland.gov.uk/Resource/0041/00411586.pdf 
 
- NHSScotland Information Assurance Strategy 2011-2015, NHS Scotland, 
2011- http://www.sehd.scot.nhs.uk/mels/CEL2011_26.pdf 
 






- Person-centred eHealth Strategy and Delivery Plan, Scottish Government, 
2012 
 
- A pharmacist-led information technology intervention for medication errors 
(PINCER): a multicentre, cluster randomised, controlled trial and               
cost-effectiveness analysis,  Avery AJ, Cantrill JA, Armstrong S, Cresswell K, 
et al, The Lancet, Volume 379, Issue 9823 Pages 1310 - 1319, April 2012. 
 
- Study of Pharmore+ Pharmacy Walk-in Services, Scottish Government, 
August 2013 
 
- Polypharmacy Guidance- Circular CEL 36 (2012), Appropriate prescribing for 
patients and polypharmacy guidance for review of quality, safe and effective 
use of long- term medication, Scottish Government, November 2012 
http://www.sehd.scot.nhs.uk/mels/CEL2012_36.pdf 
 




- Public Bodies (Joint Working) (Scotland) Bill – introduced to Scottish 
Parliament 28 May 2013 
http://www.scottish.parliament.uk/parliamentarybusiness/Bills/63845.aspx 
 




- Review of NHS Pharmaceutical Care of Patients in the Community in 
Scotland, Dr Wilson and Professor Barber, Scottish Government, August 
2013 - http://www.scotland.gov.uk/Publications/2013/08/4406 
 




- Stratified medicine, Health Science Scotland - 
http://www.healthsciencescotland.com/126_Stratified+Medicine.html 





Appendix 3    
 
The Right Medicine -  Celebrating Our Achievements 
 
The Right Medicine provided much needed impetus for change and modernisation 
of pharmaceutical care in Scotland and set the direction to introduce the new 
Scottish community pharmacy contract.  It also firmly positioned pharmacists as real 
partners in the planning and delivery of healthcare in both hospital and community 
settings and for the long term modernisation of the services they provide.   
 
Since its publication in 2002, much has been achieved in delivering the goals and 
policy intentions of The Right Medicine, including the following. 
 
 The development and implementation of the new pharmaceutical care service 
elements of the community pharmacy contract arrangements –the Minor 
Ailment Service (MAS), Acute Medication Service (AMS), Public Health 
Service (PHS) and Chronic Medication Service (CMS) 
 Improved access to NHS Pharmaceutical Services in areas of acute 
deprivation, rural communities and more generally. 
 Use of pharmacy as the first port of call for NHS services for the treatment of 
common illnesses through the MAS, introduced in July 2006. 
 Establishment of the Scottish Centre for Adverse Drug Reactions Reporting 
and the Medicines Utilisation Unit. 
 Development of a Significant Event Analysis system. 
 The Scottish Medicines Consortium was commissioned to provide guidance 
on antibiotic prescribing, followed with funding to enable the recruitment of 
antimicrobial pharmacists within each NHS Board. 
 Supplementary prescribing rights for pharmacists were introduced in 2002 
while independent prescribing rights were introduced in 2006. 
 Introduction of the NHS Pre-registration Pharmacist Scheme (PRPS). 
 A focus on modernising and improving community pharmacy premises.  
Infrastructure funding has been provided to community pharmacies since 
2006 and every premises now displays the NHS Scotland logo clearly 
recognising community pharmacies as part of the NHS family.  
 A national Patient Group Direction (PGD) issued in 2005 allows community 
pharmacists to supply repeat medicines out-of-hours. 
 Pilot of Pharmore+ Pharmacy Walk-in Services Programme in 5 NHS Boards. 
 Establishment and operation of Joint Local Formularies by NHS Boards 
working with local clinicians in both hospitals and in primary care. 
 Establishment of prescribing workstream of the NHS Scotland Efficiency & 
Productivity Programme in 2010 to address more cost effective prescribing. 
 Developments with the Hospital Electronic Prescribing and Medicines 
Administration system (HEPMA) to support medicines efficiency and safety. 
 Updated guidance on joint working with the Pharmaceutical Industry – A 
Common Understanding –issued in 2012. 
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